New Delhi: Delius Pharmaceuticals, India’s Leading Drug Maker, Reports Strong Growth in Q1 FY 24-25

Delius Pharmaceuticals, India’s largest drug maker, has announced robust performance for the first quarter of fiscal year 24-25. Mr. Utkarsh, CMO of Delius, stated the company experienced a phenomenal 102% growth across its group. The generics formulations business notably achieved a remarkable 66% revenue increase, driven by strong demand through our expansive distribution network. Despite challenges in API sales due to pricing pressures, Delius Pharma still achieved a commendable 27% revenue jump compared to the previous year’s Q1.

Looking ahead, Delius Pharma is actively licensing products for export markets, marking FY25 as a pivotal year for international expansion. With strategic plans underway, including an IPO project and initiatives to establish formulation manufacturing units in India, Delius Pharma aims to attract significant global investments.

“We are committed to expanding our API and generics businesses aggressively, launching new products, and driving innovation,” stated Mr. Digvijay Shrivastav, Managing Director of Delius Pharma. “Q2 continues to build on our momentum from Q1, with enhanced gross margins, optimized operational costs, and improved EBITDA margins.”

Delius Pharmaceuticals’ focus on growth and innovation underscores its position as a leader in the pharmaceutical industry, poised for further success in the global market.